Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Members Spar Over ‘Protected’ Speech On ‘Dr. Oz’ In Supplement Claims Enforcement

This article was originally published in The Tan Sheet

Executive Summary

FTC announces a settlement including $9 million in consumer redress for false ads for green coffee extract supplements. In a dissent, Commissioners Maureen Ohlhausen and Joshua Wright argue that comments made in TV programs are “protected non-commercial speech” and should not influence the amount of a fine.

You may also be interested in...



Weight Loss Fraud Refunds, Product Launches: Health And Wellness Industry News

Reliv says launch of Fit3 fitness and weight loss program contributed 10% to Q1 US sales; Marketplace adds Fit to workout formula portfolio; Mojo in 730 SE stores; and more news in brief.

FTC Could Open Arms For Health Claim Science In Regulatory Review

FTC is implementing Trump administration directives on "eliminating wasteful, unnecessary regulations and processes," but attempting to reduce regulated industries' compliance burden is not the same as slowing FTC enforcement against false and misleading advertising, attorneys say.

Dr. Oz As Role Model? No Defense Against FTC Action On Weight Loss Claims

Weight loss supplement Pure Green Coffee marketer demonstrated “reckless indifference” in marketing the product, beginning after learning about the benefits of green coffee bean on The Dr. Oz Show, a federal judge says.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel